Endo, S., Imai, H., Mouri, A., Tsukamoto, K., Masaki, K., Hashimoto, K., . . . Kagamu, H. Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Springer.
Chicago Style (17th ed.) CitationEndo, Satoshi, et al. Efficacy and Safety of First-line Nivolumab Plus Ipilimumab Treatment in Elderly Patients (aged ≥ 75 years) with Non-small Cell Lung Cancer. Springer.
MLA (9th ed.) CitationEndo, Satoshi, et al. Efficacy and Safety of First-line Nivolumab Plus Ipilimumab Treatment in Elderly Patients (aged ≥ 75 years) with Non-small Cell Lung Cancer. Springer.
Warning: These citations may not always be 100% accurate.